A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/11/2015
Start Date:March 2014
End Date:May 2016
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients

A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus
antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell
Lung Cancer Patients

This multicentre trial consists of an open-labelled single cohort lead-in (Part A) followed
by a phase II double-blind, randomised, placebo-controlled comparison of AZD1775 (or
placebo)and an antimitotic agent. Review by a central laboratory of fresh tumour or archival
tumour samples will be required prior to study entry to assess TP53 mutation status.
However, subjects will be allowed to enter the single cohort (Part A) regardless of TP53
mutation status (wild-type or mutant). In addition, patients in the single cohort Part

Inclusion Criteria

- Provision of informed consent prior to any study specific procedures

- Histologic or cytologic diagnosis of advanced NSCLC, excluding large cell
neuroendocrine, and mixed NSCLC/small-cell histologies

- Failure of one prior platinum-based doublet treatment for advanced NSCLC (either due
to progressive disease or toxicity)

- Measurable disease as measured by Response Evaluation Criteria in Solid Tumours
(RECIST) criteria version 1.1

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

- Mandatory availability of tumour tissue (archival or fresh if archival is not
available) for TP53 testing

- Male or female ≥18 years-of-age

- Subjects may have received radiation for palliation prior to starting study treatment
if they have recovered from the side effects of such therapy

- Absolute neutrophil count (ANC) ≥1500/μL

- Haemoglobin (Hgb) ≥9 g/dL

- Platelets ≥100,000/uL

- Adequate liver function defined as:

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal
limits (WNL) or ≤2.5 x upper limit of normal (ULN), if liver metastases are present

- Serum bilirubin WNL

- Adequate renal function

- Ability to swallow oral medication

- Fertile male subjects willing to use at least one medically acceptable form of birth
control for the duration of the study and for 2 weeks after treatment stops

- Female subjects who are not of childbearing potential and fertile female subjects of
childbearing potential who agree to use adequate contraceptive measures

- Predicted life expectancy ≥12 weeks

- Willingness and ability to comply with study and follow-up procedures

- Ability to understand the investigational nature of this study and give written
informed consent

- Most recent chemotherapy ≤21 days or have not recovered from the side effects > Grade
1.

- Use of a study drug ≤21 days or 5 half-lives (whichever is shorter) prior to the
first dose of AZD1775

- Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89)
administered ≤28 days or limited field radiation for palliation ≤7 days prior to
starting AZD1775 or has not recovered from side effects of such therapy

- Major surgical procedures ≤28 days of beginning AZD1775, or minor surgical procedures
≤7 days

- Known central nervous system (CNS) disease

- Any known hypersensitivity or contraindication to the components of study treatment
(AZD1775 and docetaxel)

- Any of the following cardiac diseases currently or within the last 6 months as
defined by New York Heart Association [NYHA] ≥ Class 2

- Pregnant or lactating

- Concurrent administration of medications or foods that are strong inhibitors of

- Serious active infection at the time of treatment, or another serious underlying
medical condition that would impair the ability of the subject to receive protocol
treatment

- Presence of other active cancers, or history of treatment for invasive cancer ≤3
years

- Psychological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol
We found this trial at
15
sites
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Englewood, CO
Click here to add this to my saved trials
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Orange Park, FL
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Pinehurst, North Carolina 28374
?
mi
from
Pinehurst, NC
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
?
mi
from
Wichita, KS
Click here to add this to my saved trials